Training and Education
Europa Biosite Acquires Stratech Scientific, Expanding Their Product Offering and Strengthening UK Customer Reach
Europa Biosite, a leading pan-European life science distribution group, today announced the acquisition of Stratech Scientific Limited by its UK subsidiary, Cambridge Bioscience. Stratech Scientific is a well-respected and long-established UK life science distributor, known for its high-quality research...
Transduction-ready viral particles
Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.
Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable...
Field-Ready, Science-Smart: Training the Next Generation of Pharma Reps
Marina Hickson Managing Director, Vivanti February 24, 2026
Pharmaceutical innovation exists to improve patient outcomes. Yet between laboratory discovery and patient benefit lies a critical intermediary: conversation. The way clinical evidence is explained, challenged and contextualised in discussions with healthcare...
Highly efficient kit yields significant populations of pure myogenic cells.
Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential.
Using a simple 3-step process of media changes and cell passaging – these advanced...
The science of aging: from cellular mechanisms to clinical potential
Aging is an unavoidable aspect of human biology. As with many biological processes, the inevitable changes which occur as we age are not driven by a single, underlying cause, but an accumulation of interconnected biological mechanisms. These result in...
Effect of iPS cell culture medium on differentiation efficiency
Researchers at the Cira Foundation (Kyoto, Japan) have published an informative study** that highlights how defined culture conditions using Amsbio StemFit™ Basic03 medium coupled with a supportive matrix (iMatrix-511) contribute to controlling hiPSC behaviour and differentiation efficiency.
The study presents...
Reference standards improve AAV production.
Amsbio announces a new range of well characterized Adeno-Associated Virus (AAV) reference standards that enable researchers to significantly improve their AAV production processes.
Adeno-associated virus can be engineered to transport DNA of interest to target cells, without any viral genes...
Training the medicine makers of tomorrow: How virtual reality is securing the UK’s life sciences future
Ivan Wall, is co-director of Resilience, a two-year, £4.3 million UK government scheme using VR to educate the next generation of medicine makers.
As the world marks International Day of Education on 24 January, the UK faces a stark reality:...
6 Signs of Change for Biopharma in 2026
What are next year’s big trends? Simon Middleton, Head, Europe Life Sciences and Partner at L.E.K. Consulting, shares his predictions.
The biopharma industry is at an inflection point going into 2026. Discoveries from the past year will be scaled, particularly...
Inclusive clinical trials will drive better health outcomes for all
Pharmaceutical research must be much more inclusive and diverse to protect global health, says Kate Shaw, of Innovative Trials.
As a sector, the life sciences industry is driven to innovate. From precision medicines to genome editing and AI-powered molecules, our...
In 2026, precision oncology trials will finally come into their own
Dr Gen Li, CEO and Founder, Phesi, looks at R&D trends for the year ahead.
Oncology indications – particularly breast, prostate and non-small-cell lung cancer – have led Phesi’s annual Most Studied Diseases list for the last four years, and...
Poorer heart health in middle age linked to increased dementia risk
People with signs of damage to their heart during middle age are more likely to develop dementia in later life, according to research funded by the British Heart Foundation and published in the European Heart Journal.1
The study, led by...
Eye prosthesis restores sight
A tiny wireless chip implanted in the back of the eye, together with a pair of high-tech glasses, have partially restored vision to people with an advanced form of age-related macular degeneration.
In a clinical trial led by Stanford Medicine...
Arbitrating innovation: Resolving IP disputes in life sciences
As biotech and AI converge, arbitration is emerging as the preferred forum for complex intellectual property disputes – particularly when the underlying science defies straightforward explanation or analysis. In this exclusive feature, Bernhard Maier, partner and head of arbitration...
At-home brain stimulation ‘prevents major depression relapse’
Up to 85% of people with depression experience relapse during treatment.
However, a new clinical study has found that at-home brain stimulation therapy helped 75% of patients stay depression-free over six months, solving a major gap in mental health care.
The...
One in 4 life sciences professionals don’t know what data their AI models use
Experts from companies including AstraZeneca, Bayer, Novartis, and Vertex shared insights into AI agents, accelerating clinical trials and skills gaps, at a recent US conference.
New data indicates a growing “scientific content crisis” that is limiting the accuracy and adoption...
How chromosomes separate accurately
UNIGE scientists have shed new light on how cell division disorders lead to certain cancers.
Cell division is a process of remarkable precision: during each cycle, the genetic material must be evenly distributed between the two daughter cells.
To achieve this,...
Potential new therapeutic target for asthma discovered
A new way to treat asthma symptoms and even repair previously irreversible lung damage could be on the horizon, following discovery of a potential new therapeutic target by scientists at the University of Aberdeen.
the inflammation of lung tissue using...
Scientists design peptide ‘switch’ that keeps Parkinson’s protein in its healthy form
Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of a protein linked to Parkinson’s disease and related dementias.
The team has successfully demonstrated...
Customised cells fight brain cancer
Scientists at UNIGE and HUG have created artificial immune cells capable of recognising and destroying glioblastoma cells.
With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.
Until now, all available...
Scripta Therapeutics aims to flip the script on disease-modifying drugs
Techbio startup Scripta Therapeutics has emerged from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery.
Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building...
New drug target identified in fight against resistant infections
The discovery of a new mechanism of resistance to common antibiotics could pave the way for improved treatments for harmful bacterial infections, a study suggests.
Targeting this defence mechanism could aid efforts to combat antimicrobial resistance (AMR), one of the...
Breaking the bias: Diverse genomics can transform dementia diagnoses
Diagnosis of complex genetic diseases is a global challenge, but genomics research remains disproportionately focused on populations of European ancestry. Inclusive, diverse research could unlock the door to new therapies, says Neil Ward, VP of PacBio EMEA.
Europeans make up...
Doing more with less in R&D: turning equipment usage data into CapEx efficiency
As budgets tighten across life sciences, many R&D organisations have realised their biggest source of waste isn’t in their science, but their operations. Johannes Solzbach, CEO and co-founder at Calira, believes greater visibility of equipment usage data can help...
Principal Investigators: The fuel of scientific progress
PIs are crucial to maintaining research integrity, says Dekel Faruhi, VP of Product Adoption at Proofig AI.
The path to becoming a Principal Investigator (PI) usually takes over a decade, beginning with undergraduate studies and culminating in the acquisition of...
AI hallucinations are eroding trust in lab tools – but there are solutions
As scientists and researchers seek to integrate AI more deeply into daily lab workflows, tackling the issue of false or misleading information has become a top priority, says Andrew Wyatt, Chief Growth Officer, Sapio Sciences.
AI is increasingly important for...
How an AI powered implant is rewriting neurological care
The frontier of neurology has begun to think for itself.
The claim follows pioneering brain surgery carried out at King Faisal Specialist Hospital and Research Centre (KFSHRC).
In June 2025, surgeons at the centre, in Riyadh, Saudi Arabia, implanted the Middle...
Next-gen medical devices could run on body’s natural sugars
A new generation of implantable medical devices powered by natural sugars in the body could help treat life-long conditions like neurodegenerative diseases, diabetes and heart conditions.
The GLUTRONICS research project, which has received over £2 million in funding, is led...
DNA molecules manoeuvred using electrical fields
New tool offers real-time control over genetic materials, with potential to accelerate disease diagnostics and genome mapping
Researchers in McGill’s Department of Physics have developed a device that can trap and study DNA molecules without touching or damaging them.
The device,...
Without the right infrastructure, the UK risks falling behind in life sciences
Dr Kath Mackay, Chief Scientific Officer at Bruntwood SciTech, insists that investment in scientific talent and research is not enough on its own. To stay globally competitive in life sciences, the UK must invest in the infrastructure and ecosystems...
